
- BioPharm International-06-15-2015
- Volume 2015 eBook
- Issue 1
Protecting Intellectual Property in Engagements with CMOs
Important IP contractual provisions should be included when working with CMOs.
Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.
Download
.
Articles in this issue
over 10 years ago
QRM Tools for Contract Biomanufacturingover 10 years ago
Fill/Finish Trendsover 10 years ago
Biopharma Advances Demand Specialized Expertiseover 10 years ago
Taking a “Development-by-Design” Approach to Cell TherapiesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.